Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population

被引:8
|
作者
Mutawi, Thuraya M. [1 ]
Zedan, Mohamed M. [2 ]
Yahya, Raida S. [1 ]
Zakria, Mahmoud M. [3 ]
El-Sawi, Mamdouh R. [4 ]
Gaedigk, Andrea [5 ,6 ]
机构
[1] Mansoura Univ, Children Hosp, Dept Labs, Fac Med, Mansoura 35516, Egypt
[2] Mansoura Univ, Dept Pediat, Fac Med, Mansoura 35516, Egypt
[3] Mansoura Univ, Urol & Nephrol Ctr, Fac Sci, Mansoura 35516, Egypt
[4] Mansoura Univ, Div Physiol, Dept Zool, Fac Sci, Mansoura 35516, Egypt
[5] Univ Missouri Kansas City, Childrens Mercy Kansas City, Div Clin Pharmacol Toxicol & Therapeut Innovat, Kansas City, MO 64108 USA
[6] Univ Missouri Kansas City, Sch Med, Kansas City, MO 64108 USA
关键词
genotype; phenotype Egyptian population; PHARMACOGENETICS IMPLEMENTATION CONSORTIUM; HUMAN CYTOCHROME-P450 2D6; POOR METABOLIZERS; CPIC GUIDELINE; CYP3A4-ASTERISK-22; POLYMORPHISMS; ALLELES; DUPLICATION; PHENOTYPE; VARIANTS;
D O I
10.2217/pgs-2020-0140
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: This study investigated major allelic variants of CYP2D6, CYP3A4 and CYP3A5 in Egyptians, an Arabic population for which there is little information regarding these important pharmacogenes. Patients & methods: CYP2D6*2, *4, *5, *10, *41 and gene copy number variation, as well as CYP3A4*22 and CYP3A5*3 were determined with commercially available TaqMan assays in 145 healthy study participants. Results: The CYP2D6 alleles identified suggest that the prevalence of poor metabolizers is low as none were found among the 145 subjects investigated. The frequency for CYP3A5 nonexpressers was 74.5% and the CYP3A4*22 allele frequency was low at 2.0%. Conclusion: These preliminary findings indicate that pharmacogene variation in Egyptians is different from those of other Middle Eastern/Arabic populations and warrants further investigation.
引用
收藏
页码:323 / 334
页数:12
相关论文
共 50 条
  • [31] Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma
    Azarpira, Negar
    Ashraf, Mohamad Javad
    Khademi, Bigan
    Darai, Masumeh
    Hakimzadeh, Afsoon
    Abedi, Elham
    MOLECULAR BIOLOGY REPORTS, 2011, 38 (08) : 5443 - 5448
  • [32] Genetic Variability of CYP4F2, CYP2D6, CYP2E1, and ACE in the Chinese Yi Population
    Guo, Jinping
    Zhou, Wenqian
    Ma, Xiaoya
    Li, Yujie
    Zhang, Huan
    Wei, Jie
    Du, Shuli
    Jin, Tianbo
    BIOCHEMICAL GENETICS, 2024, : 2812 - 2830
  • [33] Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
    Saiz-Rodriguez, Miriam
    Almenara, Susana
    Navares-Gomez, Marcos
    Ochoa, Dolores
    Roman, Manuel
    Zubiaur, Pablo
    Koller, Dora
    Santos, Maria
    Mejia, Gina
    Borobia, Alberto M.
    Rodriguez-Antona, Cristina
    Abad-Santos, Francisco
    BIOMEDICINES, 2020, 8 (04)
  • [34] Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes
    Mas, S.
    Gasso, P.
    Alvarez, S.
    Parellada, E.
    Bernardo, M.
    Lafuente, A.
    PHARMACOGENOMICS JOURNAL, 2012, 12 (03) : 255 - 259
  • [35] Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans
    Kim, Kyoung-Ah
    Park, In-Bae
    Park, Ji-Young
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (10) : 1281 - 1289
  • [36] Influence of CYP2C8, CYP3A4, and CYP3A5 Host Genotypes on Early Recurrence of Plasmodium vivax
    Almeida, Anne C. G.
    Puca, Maria C. B.
    Figueiredo, Erick F. G.
    Barbosa, Laila R.
    Salazar, Yanka E. A. R.
    Silva, Emanuelle L.
    Brito, Marcelo A. M.
    Siqueira, Andre M.
    Vieira, Jose L. F.
    Lacerda, Marcus V. G.
    Monteiro, Wuelton M.
    Melo, Gisely C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (07)
  • [37] CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes
    Hutchinson, MR
    Menelaou, A
    Foster, DJR
    Coller, JK
    Somogyi, AA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (03) : 287 - 297
  • [38] Impact of Genetic Variability in CYP2D6, CYP3A5, and ABCB1 on Serum Concentrations of Quetiapine and N-desalkylquetiapine in Psychiatric Patients
    Bakken, Gry V.
    Molden, Espen
    Hermann, Monica
    THERAPEUTIC DRUG MONITORING, 2015, 37 (02) : 256 - 261
  • [39] Frequencies of Three CYP2D6 Nonfunctional Alleles (CYP2D6☆3, ☆4, and ☆6) Within an Iranian Population (Mazandaran)
    Hashemi-Soteh, Seyed Mohammad Bagher
    Sarzare, Fatemeh
    Merat, Fatemeh
    Salehifar, Ebrahim
    Shiran, Mohammad-Reza
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2011, 15 (11) : 821 - 825
  • [40] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651